Regulatory Index News w/c 28 January 2019

Here is a selection of this week's news from around the world

 

£1.5million investment in Parkinson’s drug discovery

Parkinson’s UK says it intends to invest a further £1.5 million into its drug discovery programme aiming to develop novel gene transcription modulators for Parkinson’s.

To read more follow this PharmaTimes link 

 

Takeda's dengue vaccine meets goal in Phase 3 study

Takeda's dengue vaccine met its primary goal in the first part of a Phase 3 study testing the treatment's ability to prevent the mosquito-borne tropical disease in children and adolescents living in dengue-endemic areas in Latin America and Asia.

To read more follow this BioPharmaDive link

     
 

Roche Alzheimer's setback puts Biogen in lonely spot

Roche will not continue two late-stage studies of its Alzheimer's drug crenezumab, disclosing Tuesday that a data monitoring committee had concluded the anti-amyloid therapy was unlikely to yield a cognitive benefit for patients with early forms of the neurodegenerative disease.

To read more follow this BioPharmaDive link

 

Ultomiris successful in Phase III study

Alexion Pharmaceuticals’ Ultomiris (ravulizumab-cwvz) has been found to be successful in treating atypical haemolytic uremic syndrome (aHUS) in a Phase III study.

To read more follow this PharmaTimes link

     
 

NICE links with EMIG

The National Institute for Health and Care Excellence and the Ethical Medicines Industry Group (EMIG) are working together to increase understanding of the services the Institute offers the life sciences industry.

To read more follow this PharmaTimes link 

 

Pharma misses its prescription for growth

Caught under a microscope over drug pricing, pharmaceutical companies are predicting 2019 will bring revenue totals noticeably lower than what Wall Street expected for the year ahead.

To read more follow this BioPharmaDive link

 

L O

Author

Lorna Osborn

Date Published

31st January 2019

Come and join our community!

We are ready and waiting for you

We use cookies. By continuing to browse the site or closing this message you are agreeing to our Terms and Privacy Policy

ACCEPT and Hide This Message